NCT01457430View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Hereditary Angioedema
Interventions
DRUG

Icatibant

30 mg subcutaneous dose of Icatibant

Trial Locations (5)

17033

Penn State University, Hershey

20902

Institute for Allergy and Asthma, Wheaton

75231

AARA Research Center, Dallas

Unknown

San Diego Veterans Affairs Medical Center, La Jolla

UCLA - David Geffen School of Medicine, Los Angeles

All Listed Sponsors
collaborator

Shire Human Genetic Therapies, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01457430 - Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE | Biotech Hunter | Biotech Hunter